Acorda Loses Multiple Sclerosis Drug Patents

“Acorda Therapeutics Inc. (ACOR) announced that a federal judge in Delaware struck down four patents for its multiple sclerosis drug Ampyra. (See also, Celgene MS Drug Reports Positive Phase 3 Data.) Four Ampyra patents related to the drug delivery mechanism were invalidated by U.S. District Judge Leonard Stark” writes Shobhit Seth for Acorda managed to ink settlements with most of these drug makers, but Mylan, Teva and Roxane didn’t comply and challenged the validity of Acorda’s patents.However, one patent for the extended-release formulation of the drug was upheld; it is set to expire July 2018.

Share This:

Related posts